CRVO CervoMed
- 23.890
- -0.010-0.04%
CervoMed News
CervoMed Updates Stakeholders on Clinical and Financial Status
Disney To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Canaccord
CervoMed Is Maintained at Buy by Canaccord Genuity
CervoMed Is Maintained at Buy by Canaccord Genuity
Canaccord Genuity Maintains Buy on CervoMed, Raises Price Target to $65
Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $50 to $65.
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), CervoMed (CRVO) and Teladoc (TDOC)
CervoMed Shares Operational and Financial Insights Online
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
CervoMed GAAP EPS of -$0.82 Beats by $1.23, Revenue of $7.14M Beats by $3.09M
CervoMed 2023 Loss $2.2M >CRVO
CervoMed 2023 Loss $2.2M >CRVO
Press Release: CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates - Announced private placement of up to $149.4 million led by RA Capital Management with participati
Cervomed Inc. Braces for Impact: How Political Uncertainty and the Presidential Election Could Shake Up the Pharma Industry
CervoMed to Participate in Upcoming Investor Conferences
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company's Management will
CervoMed Shares Rise 20% After Private Placement Pricing
By Chris Wack CervoMed shares rose after the company entered into a definitive securities purchase agreement for a private placement to sell 2.5 million units. The neurological disorder-focused comp
CervoMed Prices $50 Million Equity Sale to Private Investors
CervoMed (CRVO) on Thursday priced a private sale of around 2.5 million units that are each composed of a share of common stock and a pre-funded warrant to purchase another share for $19.745. The priv
Express News | CervoMed Announces Private Placement Financing Including $50M Financing Upfront With Up To An Additional $99.4M Tied To Exercise Of Warrants
CervoMed Announces Up to $149.4 M Private Placement Financing Joined by Leading Healthcare Investors
CervoMed Announces Up to $149.4 M Private Placement Financing Joined by Leading Healthcare Investors
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersYield10 Bioscience (NASDAQ:YTEN) shares moved upwards by 71.5% to $0.42 during Thursday's regular session. The market value of their outstanding shares is at $4.9 million. Monogram Orthopaedics
CervoMed Updates Investors on Clinical and Financial Health
CervoMed Announces Presentation Of Biomarker Data From The AscenD-LB Phase 2a Trial And Preclinical Data Supporting Potential Of Neflamapimod In Tau-Mediated Disease At AD/PD 2024
- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP)- Neflamapimod effects on GFAP correlated to clinical outcomes assessed by CDR
CervoMed to Participate in the BIO CEO and Investor Conference
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company
Analysis
Price Target
No Data
